In mouse models, PD-1 deficiency on ILC2s promoted tumor control by enhancing the intra-tumoral recruitment and secretory capability of ILC2s both in primary and metastatic lesions; similar findings were obtained when mice were treated with PD-1-blocking antibodies [50,53] (Figure 2B). Here, PDCD1 is linked to neoplasm.